← Latest news 
Trump pharma tariff push hits branded drugs but exemptions shrink the damage
Economy
Published on 24 April 2026
Most major carve outs could blunt the tariff shock
The US has moved to impose tariffs on branded drug imports, aiming to spur domestic manufacturing. But the impact may be limited because key exemptions cover companies investing in US production and imports from countries with trade agreements. Generics are unaffected, leaving Indian exporters of branded medicines needing to reassess the new compliance and pricing rules.
- Tariffs target branded drug imports into the US
- Exemptions for US manufacturing investors soften the effect
- Trade agreement countries are also carved out
- Generics are not affected, but branded exports may change
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times